logo-loader
viewNeuroRx

NeuroRx aims to tackle suicide by treating bipolar depression with new therapy

NeuroRx Inc CEO Dr. Jonathan Javitt tells Proactive Investors the privately-held clinical stage biopharma company is focused on preventing suicide by treating bipolar depression with its small molecule oral drug called NRX-101.

Dr. Javitt says NRX-101 was recently granted Breakthrough Therapy Designation by the FDA for this indication, and is now entering Phase 3 clinical studies with the drug.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Algernon Pharmaceuticals receives positive feedback from...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver to discuss the company receiving positive feedback from Health Canada on the Company’s plan for a Phase Two COVID-19 clinical study in Canada, with its repurposed drug...

6 hours, 43 minutes ago

2 min read